Analysis | Metabolite Name | Measured Value | Units | Cell Type | Stimulation |
---|---|---|---|---|---|
Reversed phase NEGATIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+CL)- | 108549 | Peak area | BS4 | IL-17A |
Reversed phase NEGATIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+CL)- | Peak area | BS4 | IFN-G | |
Reversed phase NEGATIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+CL)- | Peak area | BS4 | TNF-alpha | |
Reversed phase NEGATIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+CL)- | Peak area | BS4 | TNF-alpha+IL-17A | |
Reversed phase NEGATIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+CL)- | Peak area | BS4 | Untreated | |
Reversed phase NEGATIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+CL)- | Peak area | HAHA | IFN-G | |
Reversed phase NEGATIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+CL)- | Peak area | HAHA | IL-17A | |
Reversed phase NEGATIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+CL)- | Peak area | HAHA | TNF-alpha | |
Reversed phase NEGATIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+CL)- | Peak area | HAHA | TNF-alpha+IL-17A | |
Reversed phase NEGATIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+CL)- | Peak area | HAHA | Untreated | |
Reversed phase NEGATIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+CL)- | Peak area | PAK | IFN-G | |
Reversed phase NEGATIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+CL)- | Peak area | PAK | IL-17A | |
Reversed phase NEGATIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+CL)- | Peak area | PAK | TNF-alpha | |
Reversed phase NEGATIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+CL)- | Peak area | PAK | TNF-alpha+IL-17A | |
Reversed phase NEGATIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+CL)- | Peak area | PAK | Untreated | |
Reversed phase NEGATIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+HCOO)- | 1989 | Peak area | PAK | TNF-alpha+IL-17A |
Reversed phase NEGATIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+HCOO)- | 3387 | Peak area | HAHA | TNF-alpha+IL-17A |
Reversed phase NEGATIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+HCOO)- | 8687 | Peak area | PAK | TNF-alpha |
Reversed phase NEGATIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+HCOO)- | 11259 | Peak area | HAHA | IL-17A |
Reversed phase NEGATIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+HCOO)- | 34227 | Peak area | BS4 | IL-17A |
Reversed phase NEGATIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+HCOO)- | 38838 | Peak area | PAK | IFN-G |
Reversed phase NEGATIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+HCOO)- | 42100 | Peak area | BS4 | TNF-alpha+IL-17A |
Reversed phase NEGATIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+HCOO)- | 49768 | Peak area | PAK | IL-17A |
Reversed phase NEGATIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+HCOO)- | 54629 | Peak area | BS4 | IFN-G |
Reversed phase NEGATIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+HCOO)- | 54757 | Peak area | BS4 | Untreated |
Reversed phase NEGATIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+HCOO)- | 80236 | Peak area | BS4 | TNF-alpha |
Reversed phase NEGATIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+HCOO)- | Peak area | HAHA | IFN-G | |
Reversed phase NEGATIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+HCOO)- | Peak area | HAHA | TNF-alpha | |
Reversed phase NEGATIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+HCOO)- | Peak area | HAHA | Untreated | |
Reversed phase NEGATIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+HCOO)- | Peak area | PAK | Untreated | |
Reversed phase POSITIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+H)+ | 58400 | Peak area | PAK | TNF-alpha |
Reversed phase POSITIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+H)+ | 76948 | Peak area | PAK | TNF-alpha+IL-17A |
Reversed phase POSITIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+H)+ | 100059 | Peak area | HAHA | Untreated |
Reversed phase POSITIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+H)+ | 114324 | Peak area | HAHA | TNF-alpha |
Reversed phase POSITIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+H)+ | 223472 | Peak area | HAHA | IL-17A |
Reversed phase POSITIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+H)+ | 226817 | Peak area | HAHA | TNF-alpha+IL-17A |
Reversed phase POSITIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+H)+ | 528564 | Peak area | HAHA | IFN-G |
Reversed phase POSITIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+H)+ | 858381 | Peak area | PAK | Untreated |
Reversed phase POSITIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+H)+ | 901686 | Peak area | BS4 | IL-17A |
Reversed phase POSITIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+H)+ | 1387975 | Peak area | PAK | IFN-G |
Reversed phase POSITIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+H)+ | 1430397 | Peak area | PAK | IL-17A |
Reversed phase POSITIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+H)+ | 1551741 | Peak area | BS4 | TNF-alpha+IL-17A |
Reversed phase POSITIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+H)+ | 1717794 | Peak area | BS4 | IFN-G |
Reversed phase POSITIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+H)+ | 1969612 | Peak area | BS4 | Untreated |
Reversed phase POSITIVE ION MODE | ADENOSINE (CAS# 58-61-7); (M+H)+ | 2382960 | Peak area | BS4 | TNF-alpha |